← All organizations
Highest phase reached
Phase 4
First clinical trial
Jun 1, 1996Last known activity
Oct 31, 2025
Timeline
1970s
- Jan 1, 1973
PETHEMA Foundation— Founded
Drugs by trial phase (88 distinct, 85 trials)
Phase 4 (41 own, 0 via acquisition)
Phase 3 (13 own, 0 via acquisition)
Phase 2 (32 own, 0 via acquisition)
Phase 1 (2 own, 0 via acquisition)
Indications
Studied for
- Acquired Immunodeficiency Syndrome
- Aggression
- Amyloidosis
- Aspergillosis
- Burkitt Lymphoma
- Communicable Diseases
- Cytomegalovirus Infections
- HIV Infections
- Immunoglobulin Light-chain Amyloidosis
- Infections
- Invasive Pulmonary Aspergillosis
- Ischemia
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Leukemia, Myeloid, Chronic-Phase
- Leukemia, Promyelocytic, Acute
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
- Multiple Myeloma
- Mycoses
- Myelodysplastic Syndromes
- Nausea
- Neoplasm Metastasis
- Neoplasms, Plasma Cell
- Philadelphia Chromosome
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Preleukemia
- Pulmonary Aspergillosis
- Recurrence
- Renal Insufficiency
- Smoldering Multiple Myeloma
- Syndrome
Recent trials (50)
- NCT07107529CollaboratorPhase 2Oct 31, 2025
- NCT07045909Lead sponsorPhase 2Jun 30, 2025
- NCT06574126Lead sponsorPhase 2Sep 30, 2024
- NCT06544785Lead sponsorPhase 2Sep 2, 2024
- NCT05849610Lead sponsorPhase 2Nov 30, 2023
- NCT06282978Lead sponsorPhase 2Nov 23, 2023
- NCT05558319Lead sponsorPhase 3Oct 31, 2022
- NCT05527340Lead sponsorPhase 2Sep 30, 2022
- NCT05060627Lead sponsorPhase 1/Phase 2Dec 15, 2021
- NCT04802356Lead sponsorPhase 2Apr 7, 2021
- NCT04687761Study chairPhase 1/Phase 2Nov 4, 2020
- NCT04687761Lead sponsorPhase 1/Phase 2Nov 4, 2020
- NCT04230239Study chairPhase 2Dec 26, 2019
- NCT04230239Lead sponsorPhase 2Dec 26, 2019
- NCT04178798Study chairPhase 3Dec 9, 2019
Details
- Founded
- Madrid, ES Jan 1, 1973
- Last known activity
- Oct 31, 2025